Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 21 to 30 of 290 total matches.
In Brief: Femlyv – An Orally Disintegrating Hormonal Contraceptive
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024 (Issue 1717)
In Brief: Femlyv – An Orally Disintegrating Hormonal Contraceptive ...
Femlyv (Millicent), an orally disintegrating tablet
containing ethinyl estradiol and norethindrone
acetate, has been approved by the FDA for prevention
of pregnancy in females with a body mass index (BMI)
≤35 kg/m2. It is the first hormonal contraceptive to
become available in an orally disintegrating tablet
formulation. Traditional oral and chewable tablets
containing ethinyl estradiol and norethindrone acetate
in a wide range of doses, including those found in
Femlyv, have been available in the US for years.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):200 doi:10.58347/tml.2024.1717c | Show Introduction Hide Introduction
In Brief: Warning about Drospirenone in Oral Contraceptives
The Medical Letter on Drugs and Therapeutics • Apr 30, 2012 (Issue 1389)
In Brief: Warning about Drospirenone in Oral Contraceptives ...
The FDA has announced that combination hormonal contraceptives (CHCs) containing the synthetic progestin drospirenone (Yaz, Yasmin, Beyaz, Safyral, and others) may be associated with a higher risk of thromboembolism than CHCs containing other progestins.1The new warning was based partly on an unpublished, FDA-funded, retrospective study that found a 1.7-times higher risk of venous thromboembolism among US women who used a CHC that contained drospirenone than among women whose CHC contained levonorgestrel, norgestimate or norethindrone as the progestin component.2 As with all retrospective...
A Subdermal Progestin Implant For Long-Term Contraception
The Medical Letter on Drugs and Therapeutics • Mar 08, 1991 (Issue 839)
A Subdermal Progestin Implant For Long-Term Contraception ...
The Norplant System (Wyeth-Ayerst) for subdermal delivery of the synthetic progestin levonorgestrel was recently approved by the US Food and Drug Administration for use as a long-term contraceptive.
Plan B: A Progestin-Only Emergency Contraceptive
The Medical Letter on Drugs and Therapeutics • Jan 24, 2000 (Issue 1070)
Plan B: A Progestin-Only Emergency Contraceptive ...
The FDA has approved marketing of Plan B (Women's Capital Corporation), an emergency contraceptive "pill pack"that contains two 0.75-mg tablets of levonorgestrel.
In Brief: Femcon Fe: A Chewable Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Feb 26, 2007 (Issue 1255)
In Brief: Femcon Fe: A Chewable Oral Contraceptive ...
Femcon Fe (Warner Chilcott) is being advertised as the world's only chewable oral contraceptive. It was formerly marketed as Ovcon 35 Fe. Each packet provides 21 tablets containing 0.4 mg norethindrone and 35 mcg ethinyl estradiol, and 7 tablets with only 75 mg of ferrous fumarate. Femcon Fe has the same active hormonal ingredients as Ovcon 35 (Warner Chilcott), which has been available since 1976, and its generic equivalent Balziva (Barr); neither formulation contains iron. The spearmint-flavored Femcon Fe pill can be chewed or swallowed whole. According to the package labeling, if the pill...
Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020 (Issue 1591)
Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive ...
The FDA has approved a progestin-only oral
contraceptive ("minipill") containing drospirenone
(Slynd – Exeltis). All other progestin-only oral
contraceptives available in the US contain
norethindrone (Camila, and others). Progestin-only oral
contraceptives are similar in efficacy to combination
oral contraceptives. They are used predominantly by
breastfeeding women and by those in whom estrogen
is poorly tolerated or contraindicated. Combination
oral contraceptives containing drospirenone and
ethinyl estradiol have been available for years.
Estetrol/Drospirenone (Nextstellis) - A New Combination Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
Estetrol/Drospirenone (Nextstellis) - A New Combination Oral Contraceptive ...
The FDA has approved a combination oral
contraceptive containing the estrogen estetrol and the
progestin drospirenone (Nextstellis – Mithra/Mayne).
Estetrol is the first new estrogen to become available
in the US in 50 years. Drospirenone is available alone
(Slynd) and in combinations with the estrogen ethinyl
estradiol for prevention of pregnancy.
Quartette: An Ascending-Dose, Extended-Cycle Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Jul 08, 2013 (Issue 1420)
Quartette: An Ascending-Dose, Extended-Cycle Oral Contraceptive ...
The FDA has approved Quartette (Teva), an extended-cycle
combination oral contraceptive containing increasing
doses of the estrogen ethinyl estradiol (EE)
combined with the progestin levonorgestrel (LNG). The
rationale is that a gradual increase in the EE dose may
reduce unscheduled bleeding or spotting, a common
adverse effect of extended-cycle oral contraceptives.
A Progestin-Releasing Intrauterine Device For Long-Term Contraception
The Medical Letter on Drugs and Therapeutics • Jan 22, 2001 (Issue 1096)
A Progestin-Releasing Intrauterine Device For Long-Term Contraception ...
The FDA had approved an intrauterine contraceptive device that releases the synthetic progestin levonorgestrel over a period of five years. The device has been available in Europe for 10 years.
Addendum: Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Mar 23, 2020 (Issue 1594)
Addendum: Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive ...
In our article on Slynd (Med Lett Drugs Ther 2020; 62:18),
the drospirenone-only oral contraceptive, we mentioned that
drospirenone has antiandrogenic activity that could improve
acne and antimineralocorticoid activity that could cause
hyperkalemia. We should have added that concurrent use of
drospirenone with other drugs that increase potassium levels,
such as the anti-androgen aldosterone receptor antagonist
spironolactone (Aldactone, and generics), which is often
used off-label for treatment of acne, can increase the risk of
hyperkalemia.